Invasive fungal infections and (1,3)-β-D-glucan serum concentrations in long-term intensive care patients

被引:47
|
作者
Presterl, Elisabeth [1 ]
Parschalk, Bernhard [1 ,2 ]
Bauer, Edith [3 ]
Lassnigg, Andrea [4 ]
Hajdu, Stefan [5 ]
Graninger, Wolfgang [1 ]
机构
[1] Med Univ Vienna, Div Infect Dis, Dept Med 1, Allgemeines Krankenhaus, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Otorhinol, Allgemeines Krankenhaus, A-1090 Vienna, Austria
[3] Med Univ Vienna, Dept Med 3, Allgemeines Krankenhaus, Div Nephrol, A-1090 Vienna, Austria
[4] Med Univ Vienna, Dept Anaesthesia & Gen Intens Care Med, Allgemeines Krankenhaus, Div Cardiothorac Anaesthesia, A-1090 Vienna, Austria
[5] Med Univ Vienna, Dept Trauma Surg, Allgemeines Krankenhaus, A-1090 Vienna, Austria
关键词
Fungal infection; Diagnosis; (1,3)-beta-D-Glucan; Intensive care unit; CRITICALLY-ILL PATIENTS; BETA-D-GLUCAN; EARLY-DIAGNOSIS; CANDIDA COLONIZATION; SYSTEMIC CANDIDIASIS; ASSAY; MULTICENTER; LEUKEMIA; TESTS;
D O I
10.1016/j.ijid.2008.10.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: Invasive fungal infections are associated with high morbidity and increased mortality. This study was performed to assess the epidemiology of fungal infections and to determine (1,3)beta-D-glucan serum concentrations in patients admitted to intensive care units (ICUs). Patients and methods: Overall 197 patients were admitted to nine medical and surgical intensive care units (ICUs) at a 2200-bed university hospital during a 3-month period. Retrospectively, the patients were split into three groups: group A comprised 24 patients with proven invasive fungal infections admitted for a median of 40 days. Group B comprised 58 patients who were admitted to the ICU for 30 days but without fungal infection. One hundred and fifteen post-operative patients served as controls (group C). The levels of (1,3)-beta-D-glucan were monitored in all patients twice weekly during their ICU admittance. Results: Average (1,3)-beta-D-glucan concentrations were significantly higher in the patients with fungal infections compared to group B and group C (median 44 vs. 22 and 12.9 pg/ ml, respectively; p < 0.001). For a serum (1,3)-beta-D-glucan level of 40 pg/ ml, the sensitivity, the specificity, the positive predictive value, the negative predictive value, the area under the curve of the receiver operating characteristics (AUC ROC) curve, the likelihood ratio (LR)+ and LR-were 52.2, 75.9, 46.2, 80, 0.7, 2.16, and 0.63, respectively, on day 7. Patients in group A had bacterial infections significantly more often than patients in group B (p = 0.003). The hospitalization before ICU admittance for group A was significantly longer than for groups B and C (median 19 (group A) vs. 6 (group B) vs. 10 (group C) days; p < 0.05). Conclusions: Longer hospitalization and multiple bacterial infections were found to be the main risk factors for invasive fungal infections. Long-term ICU patients have elevated (1,3)-beta-D-glucan levels, not only due to invasive fungal infections, but also due to the serious underlying diseases and conditions, inter-current complications, and intensive care measures. Yet, persistently high serum levels of (1,3)-beta-D-glucan in ICU patients may be indicative of invasive fungal infections and warrant additional diagnostic efforts. (C) 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:707 / 712
页数:6
相关论文
共 50 条
  • [31] Evaluation of the clinical cutoff level of serum (1 → 3)-β-d-glucan in patients with connective tissue diseases complicated by deep fungal infections
    Kato, Kenichi
    Onoda, Satoru
    Asano, Junichiro
    Fukaya, Shusaku
    Yoshida, Shunji
    MODERN RHEUMATOLOGY, 2010, 20 (04) : 366 - 369
  • [32] Clinical Usefulness of Serum (1,3)-β-D-glucan to predict invasive candidiasis in patients with severe burn trauma
    Lee, Nuri
    Kym, Dohern
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2022, 55 (01) : 138 - 146
  • [33] Serum (1,3)-β-D-Glucan for Screening of Neonatal Fungemia
    Kamirul Islam
    Nazima Khatun
    Ujjal Mondal
    Kuntalkanti Das
    Kaustav Nayek
    Indian Pediatrics, 2022, 59 : 499 - 500
  • [34] Serum (1,3)-β-D-Glucan for Screening of Neonatal Fungemia
    Islam, Kamirul
    Khatun, Nazima
    Mondal, Ujjal
    Das, Kuntalkanti
    Nayek, Kaustav
    INDIAN PEDIATRICS, 2022, 59 (06) : 499 - 500
  • [35] High level of β-(1,3)-D-glucan antigenaemia in cystic fibrosis in the absence of invasive fungal disease
    Rautemaa, Vilma
    Green, Heather D.
    Jones, Andrew M.
    Rautemaa-Richardson, Riina
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2017, 88 (04) : 316 - 321
  • [36] Retrospective assessment of β-D-(1,3)-glucan for presumptive diagnosis of fungal infections
    Bellanger, Anne-Pauline
    Grenouillet, Frederic
    Henon, Thierry
    Skana, Florence
    Legrand, Faezeh
    Deconinck, Eric
    Millon, Laurence
    APMIS, 2011, 119 (4-5) : 280 - 286
  • [37] Diagnostic Performance of the (1→3)-β-D-Glucan Assay for Invasive Fungal Disease
    Koo, Sophia
    Bryar, Julie M.
    Page, John H.
    Baden, Lindsey R.
    Marty, Francisco M.
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (11) : 1650 - 1659
  • [38] Usage of 1,3-β-D-Glucan for Early Detection of Invasive Mycoses and Outcome Parameter in Immunocompromised Critically Ill Patients
    Lahmer, Tobias
    Held, Juergen
    Rasch, Sebastian
    Schnappauf, Christopher
    Beitz, Analena
    Schmid, Roland M.
    Huber, Wolfgang
    MYCOPATHOLOGIA, 2016, 181 (11-12) : 815 - 821
  • [39] Clinical Performance of the (1,3)-β-D-Glucan Assay in Early Diagnosis of Nosocomial Candida Bloodstream Infections
    Del Bono, Valerio
    Delfino, Emanuele
    Furfaro, Elisa
    Mikulska, Malgorzata
    Nicco, Elena
    Bruzzi, Paolo
    Mularoni, Alessandra
    Bassetti, Matteo
    Viscoli, Claudio
    CLINICAL AND VACCINE IMMUNOLOGY, 2011, 18 (12) : 2113 - 2117
  • [40] Prognostic Impact of Negative Serum (1,3)-β-D-glucan in Patients With Candidemia Reply
    Agnelli, Caroline
    Valerio, Maricela
    Bouza, Emilio
    Munoz, Patricia
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (04) : 1126 - 1126